-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Figure: This figure shows how an increase in the level of sST2 in AD impairs microglia clearance of amyloid pathology: an increase in the level of sST2 protein (1) in the blood enters the brain; This bait receptor blocks the normal signaling of IL-33 stimulation in microglia (2
Source: The Hong Kong University of Science and Technology
An international research team led by Professor Morningside Life Sciences at the Hong Kong University of Science and Technology (HKUST) and Professor Hin-Ying Ip, Director of the Hong Kong Centre for Neurodegenerative Diseases (HKCeND), has discovered a blood protein that plays an important role
Alzheimer's disease is currently an irreversible disease that lacks effective treatments and affects more than 50 million people
Now, the team has discovered a blood protein, soluble ST2 (sST2), which plays a key role
The team further found that sST2 levels are regulated
Taken together, these key findings open up new possibilities for treatment with AD, the main purpose of which is to reduce sST2 levels
"This exciting work not only further deepens our understanding of AD and identifies an excellent drug target for developing therapeutic drugs, but also clearly demonstrates the importance of
This work was supported by the HKSAR Government's Innovation Hong Kong Initiative and in collaboration with researchers at University College London and Stanford University, clinicians at Prince of Wales Hospital, the University of Melbourne and Edith Cowan University
Article title
An IL1RL1 genetic variant lowers soluble ST2 levels and the risk effects of APOE-ε4 in female patients with Alzheimer’s disease
